Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer is a devastating disease. Previous research shows a correlation between a
specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs
combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination
for locally advanced and metastatic pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Spectrum Health Hospitals
Collaborators:
Battle Creek Health System Eli Lilly and Company Hackley Hospital Mecosta County General Hospital Mercy Health System Metropolitan Hospital, Michigan Munson Medical Center Saint Mary's Health Care Saint Mary's Health Network Van Andel Research Institute